- Home
- BGLC vs AEON Comparison
BGLC vs AEON Comparison
Compare BGLC & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- AEON
- Stock Information
- Founded
- BGLC 2017
- AEON N/A
- Country
- BGLC Malaysia
- AEON United States
- Employees
- BGLC N/A
- AEON N/A
- Industry
- BGLC Medical Specialities
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- AEON Health Care
- Exchange
- BGLC Nasdaq
- AEON Nasdaq
- Market Cap
- BGLC 5.8M
- AEON 5.9M
- IPO Year
- BGLC N/A
- AEON N/A
- Fundamental
- Price
- BGLC $0.24
- AEON $0.46
- Analyst Decision
- BGLC
- AEON Strong Buy
- Analyst Count
- BGLC 0
- AEON 1
- Target Price
- BGLC N/A
- AEON $360.00
- AVG Volume (30 Days)
- BGLC 1.4M
- AEON 4.7M
- Earning Date
- BGLC 05-14-2025
- AEON 03-24-2025
- Dividend Yield
- BGLC N/A
- AEON N/A
- EPS Growth
- BGLC N/A
- AEON N/A
- EPS
- BGLC N/A
- AEON 72.93
- Revenue
- BGLC $9,259,858.00
- AEON N/A
- Revenue This Year
- BGLC N/A
- AEON N/A
- Revenue Next Year
- BGLC N/A
- AEON N/A
- P/E Ratio
- BGLC N/A
- AEON $0.01
- Revenue Growth
- BGLC N/A
- AEON N/A
- 52 Week Low
- BGLC $0.21
- AEON $0.40
- 52 Week High
- BGLC $1.00
- AEON $626.40
- Technical
- Relative Strength Index (RSI)
- BGLC 40.98
- AEON 24.04
- Support Level
- BGLC $0.23
- AEON $0.50
- Resistance Level
- BGLC $0.32
- AEON $0.61
- Average True Range (ATR)
- BGLC 0.03
- AEON 0.08
- MACD
- BGLC -0.00
- AEON 0.41
- Stochastic Oscillator
- BGLC 41.17
- AEON 3.43
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.